Advanced Solid Tumors Clinical Trials

72 studies are recruiting for advanced solid tumors in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

   This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   11 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06413680 on ClinicalTrials.gov

2. A Study of MGC028 in Participants With Advanced Solid Tumors

   The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally ad…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF - Helen Diller Family Cancer Center, San Francisco, California

   Locations

   7 in total

   Run by

   MacroGenics

   See if you can join NCT06723236 on ClinicalTrials.gov

3. A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

   This is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer. CKD-703 is composed of a c-Met-targeting monoclonal antibody (mAb)…

   Stage

   Phase 1

   Ages

   19 and older

   Site

   Gabrail Cancer Center, Ohio City, Ohio

   Run by

   Chong Kun Dang Pharmaceutical

   See if you can join NCT07439094 on ClinicalTrials.gov

4. Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

   The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Cancer Center, Palo Alto, California

   Locations

   6 in total

   Run by

   Gilead Sciences

   See if you can join NCT06532565 on ClinicalTrials.gov

5. Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

   The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health, Scottsdale, Arizona

   Locations

   7 in total

   Run by

   Tagworks Pharmaceuticals BV

   See if you can join NCT06959706 on ClinicalTrials.gov

6. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

   The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   10 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT07262619 on ClinicalTrials.gov

7. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

   A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or tr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mid West, Grand Rapids, Michigan

   Locations

   9 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06804824 on ClinicalTrials.gov

8. SNV4818 in Participants With Advanced Solid Tumors

   This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California

   Locations

   12 in total

   Run by

   Pikavation Therapeutics, Inc.

   See if you can join NCT06736704 on ClinicalTrials.gov

9. Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

   This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing recommendations for pralatrexate administered once weekly for 6 weeks of ev…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University - Feinberg School of Medicine, Chicago, Illinois

   Locations

   4 in total

   Run by

   Acrotech Biopharma Inc.

   See if you can join NCT07036133 on ClinicalTrials.gov

10. A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

    The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Irvine (UCI) Health - UC Irvine Medical Center, Irvine, California

    Locations

    21 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06697197 on ClinicalTrials.gov

11. Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

    This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Dallas, Dallas, Texas

    Locations

    4 in total

    Run by

    Auricula Biosciences Inc.

    See if you can join NCT07148128 on ClinicalTrials.gov

12. A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

    The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Irving Medical Center, New York, New York

    Locations

    4 in total

    Run by

    AskGene Pharma, Inc.

    See if you can join NCT05867420 on ClinicalTrials.gov

13. JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

    This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    4 in total

    Run by

    Jacobio Pharmaceuticals Co., Ltd.

    See if you can join NCT06973564 on ClinicalTrials.gov

14. A Clinical Study of YL205 in Patients With Advanced Solid Tumors

    This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute (SCRI)- Denver, Denver, Colorado

    Locations

    43 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06459973 on ClinicalTrials.gov

15. BTM-3566 in Advanced Solid Tumors

    The goal of this clinical trial is to learn about what doses of BTM-356 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of BTM-3566 are in treating cancer. The main questions it aims to answer are: What adverse events and toxic…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Houston, Houston, Texas

    Locations

    2 in total

    Run by

    Bantam Pharmaceuticals

    See if you can join NCT07266285 on ClinicalTrials.gov

16. PAS-004 in Patients With Advanced Solid Tumors

    The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate diff…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MBAL Sveta Sofia, Sofia,

    Locations

    7 in total

    Run by

    Pasithea Therapeutics Corp.

    See if you can join NCT06299839 on ClinicalTrials.gov

17. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

    This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site 111, Tucson, Arizona

    Locations

    107 in total

    Run by

    DualityBio Inc.

    See if you can join NCT05914116 on ClinicalTrials.gov

18. A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

    This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanc…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars Sinai Medical Center, Los Angeles, California

    Locations

    8 in total

    Run by

    LigaChem Biosciences, Inc.

    See if you can join NCT05941507 on ClinicalTrials.gov

19. A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

    This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutat…

    Stage

    Phase 1

    Ages

    18 to 89

    Site

    Sarah Cannon Research Institute at HealthOne, Denver, Colorado

    Locations

    10 in total

    Run by

    Eikon Therapeutics

    See if you can join NCT06907043 on ClinicalTrials.gov

20. To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

    ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology, Lake City, Florida

    Locations

    24 in total

    Run by

    Abion Inc

    See if you can join NCT05541822 on ClinicalTrials.gov

21. Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

    This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio

    Locations

    3 in total

    Run by

    Shanghai YingLi Pharmaceutical Co. Ltd.

    See if you can join NCT06096974 on ClinicalTrials.gov

22. Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

    This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors. ODC-IL2 is a conditionally activated IL-2 prodrug and will be administered as a single…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth, Scottsdale, Arizona

    Run by

    Trutino Biosciences Inc.

    See if you can join NCT06770764 on ClinicalTrials.gov